Pages that link to "Q42272216"
Jump to navigation
Jump to search
The following pages link to Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment (Q42272216):
Displaying 50 items.
- Hepatotoxicity Secondary to Chemotherapy (Q26861560) (← links)
- Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis (Q28335980) (← links)
- Chronic liver injury induced by drugs: a systematic review. (Q30278737) (← links)
- Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results (Q33718601) (← links)
- Adverse events in IBD: to stop or continue immune suppressant and biologic treatment (Q34073191) (← links)
- Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes (Q34153004) (← links)
- The practical use of methotrexate in psoriasis (Q34295890) (← links)
- Review article: monitoring for drug side-effects in inflammatory bowel disease (Q34585315) (← links)
- Hepatotoxicity of methotrexate in rheumatic diseases (Q34684662) (← links)
- Methotrexate hepatotoxicity (Q34743511) (← links)
- Comparative tolerability of systemic treatments for plaque-type psoriasis (Q34967008) (← links)
- Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases (Q35049306) (← links)
- Methotrexate and psoriasis in the era of new biologic agents (Q35630761) (← links)
- Genetic and acquired factors that influence individual susceptibility to alcohol-associated liver disease (Q35779532) (← links)
- Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B. (Q36633607) (← links)
- Changes in liver biochemistry during methotrexate use for inflammatory bowel disease (Q37693666) (← links)
- Mechanistic review of drug-induced steatohepatitis (Q38581885) (← links)
- Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity (Q38687132) (← links)
- Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials (Q39128261) (← links)
- Methotrexate in psoriasis: revised guidelines (Q39514650) (← links)
- Liver toxicity of retinoid therapy (Q39518806) (← links)
- Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis (Q39617414) (← links)
- Psoralen photochemotherapy (Q39679832) (← links)
- Therapeutic approaches to the treatment of rheumatoid disease. (Q39728462) (← links)
- Liver test abnormalities in patients admitted for severe psoriasis: prevalence and associated risk factors (Q39735574) (← links)
- Hazards of therapy (Q40100209) (← links)
- Reappraisal of the use of methotrexate in rheumatic disease (Q40162216) (← links)
- Psoriasis. A review of recent advances in treatment (Q40189659) (← links)
- Methotrexate guidelines--revised (Q40326046) (← links)
- What's new: A review of advances in therapy (Q40353757) (← links)
- Advances and issues in the pharmacotherapy of rheumatoid arthritis (Q40434105) (← links)
- Modifications of PUVA. (Q41094998) (← links)
- Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists (Q41473922) (← links)
- Methotrexate use in psoriasis and psoriatic arthritis (Q41635862) (← links)
- Discontinuation of Methotrexate Treatment in Juvenile Rheumatoid Arthritis (Q41646822) (← links)
- Systemic treatment of severe psoriasis (Q41683565) (← links)
- The use of methotrexate in childhood rheumatic diseases (Q41722903) (← links)
- Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis (Q42277986) (← links)
- Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid (Q43013514) (← links)
- Low dose pulse methotrexate in rheumatoid arthritis: an 8-year experience with hepatotoxicity (Q43905700) (← links)
- End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome (Q46699120) (← links)
- Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages (Q46817799) (← links)
- Biochemical effects of methotrexate in isolated hepatocytes in relation to its steatogenic activity (Q47790292) (← links)
- Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. (Q51032239) (← links)
- Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. (Q52925161) (← links)
- [S3-Guidelines for the therapy of psoriasis vulgaris]. (Q52928363) (← links)
- Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. (Q55082101) (← links)
- Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up (Q68636708) (← links)
- Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment (Q68719764) (← links)
- Short-term methotrexate administration by low-dose infusion--does it influence clearance of psoriasis? (Q69392934) (← links)